A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment
ClinicalTrials.gov · NCT01253304 · Registry updated: 2014-10-07
- Condition / research focus
- Diabetes Mellitus, Type 2
- Sponsor
- Eli Lilly and Company
- Countries with listed sites
- Germany · Hungary
- Registry dates and results
- Start: 2010-11. Completion: 2011-11 (may be estimated). Results are posted in this registry.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- LY2189265 (drug) — also listed as: Dulaglutide
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.Munich, Germany